ImmunityBio (IBRX) Financial Analysis & Valuation | Quarter Chart
ImmunityBio (IBRX)
IBRXPrice: $8.77
Fair Value: 🔒
🔒score
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells... more
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat ... more
Description
Shares
| Market Cap | $9.19B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Richard Gerald Adcock |
| IPO Date | 2015-07-28 | CAGR | 0.55% |
| Employees | 671 | Website | immunitybio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
IBRX chart loading...
Fundamentals
Technicals
| Enterprise Value | $9.80B | P/E Ratio | -27.41 |
| Forward P/E | 145.17 | PEG Ratio | — |
| P/S Ratio | 74.95 | P/B Ratio | -11.91 |
| P/CF Ratio | -35.18 | P/FCF Ratio | -35.36 |
| EPS | $-0.32 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 351.53% | Gross Margin | 0.94% |
| Operating Margin | -1.85% | Profit Margin | -6.06% |
| ROE | 1.39% | ROA | -1.32% |
| ROCE | -0.45% | Current Ratio | 6.67 |
| Quick Ratio | 6.66 | Cash Ratio | 3.02 |
| Debt/Equity | -1.29 | Interest Coverage | -2.33 |
| Altman Z Score | -6.18 | Piotroski Score | 3 |